Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial

Cancer Gene Therapy volume 14, pages 717–723 (2007)Cite this article

Abstract

Effective eradication of established tumor and generation of a lasting systemic immune response are the goals of cancer immunotherapy. The objective of this phase IB study was to assess the safety and toxicity of treatment to metastatic tumor underlying the skin with the DNA encoding interleukin-12 (IL-12). This treatment strategy allowed the patient's own tumor to serve as a source of autologous antigen in the tumor microenvironment. We proposed that IL-12 protein produced by the transfected cells would result in the generation of both a local and systemic antitumor response. The tumor was treated with either three or six intratumoral injections of plasmid containing IL-12 DNA. This treatment strategy resulted in no significant local or systemic toxicity. The treatment did not result in an increase in serum IL-12 protein. The size of the treated lesion decreased significantly (greater than 30%) in five of the 12 patients. However, nontreated subcutaneous lesions or other disease did not decrease in size.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Abbreviations

IL:

interleukin

IFN:

interferon

References

  1. Leroy P, Slos P, Homann H, Erbs P, Poitevin Y, Regulier E et al. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res Immunol 1998; 49: 681–684.

    Article  Google Scholar 

  2. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang N-S . Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303–1311.

    Article  CAS  PubMed  Google Scholar 

  3. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049–1058.

    Article  CAS  PubMed  Google Scholar 

  4. Fernandez NC, Levraud JP, Haddada H, Perricaudet M, Kourilsky P . High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 1999; 162: 609–617.

    CAS  PubMed  Google Scholar 

  5. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld R . Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998; 95: 2475–2480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G . Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612–1621.

    CAS  PubMed  Google Scholar 

  7. Pham-Nguyen KB, Yang W, Saxena R, Thung SN, Woo SL, Chen SH . Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int J Cancer 1999; 81: 813–819.

    Article  CAS  PubMed  Google Scholar 

  8. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29: 1390–1396.

    Article  CAS  PubMed  Google Scholar 

  9. Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE et al. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. J Immunol 1999; 163: 1943–1950.

    CAS  PubMed  Google Scholar 

  10. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang N-S . Interleukin 12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T cell-independent mechanism. Cancer Gene Therapy 2000; 7: 826–838.

    Article  CAS  PubMed  Google Scholar 

  11. Cui J, Shin T, Kawano T, Sato H, Kondo I, Toura I et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623–1626.

    Article  CAS  PubMed  Google Scholar 

  12. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al. Recombinant IL-12 administration induces tumor regression in associated with IFN-γ production. J Immunol 1994; 153: 1697–1706.

    CAS  PubMed  Google Scholar 

  13. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK . Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphas Tumor Immunol 1995; 17: 71–75.

    Article  CAS  Google Scholar 

  14. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP et al. Interleukin 12 induces stable priming for interferon γ (IFN-γ) producing during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cells clones. J Exp Med 1994; 179: 1273–1283.

    Article  CAS  PubMed  Google Scholar 

  15. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994; 6: 157–167.

    Article  CAS  PubMed  Google Scholar 

  16. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156: 693–699.

    CAS  PubMed  Google Scholar 

  17. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA . The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927–932.

    CAS  PubMed  Google Scholar 

  18. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581–586.

    Article  CAS  PubMed  Google Scholar 

  19. Rakhmilevich AL, Turner J, Ford MJ, McCadbe D, Sun WH, Sondel PM et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291–6296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT . Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci 1996; 795: 275–283.

    Article  CAS  PubMed  Google Scholar 

  21. Golab J, Zagozdzon R . Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med 1999; 3: 537–544.

    CAS  PubMed  Google Scholar 

  22. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902–908.

    CAS  PubMed  Google Scholar 

  23. Marshall E . Cancer trial of interleukin-12 halted. Science 1995; 268: 1555.

    Article  Google Scholar 

  24. Car BD, Eng VM, Lipman JM, Anderson TD . The toxicology of interleukin-12: A review. Tox Path 1999; 27: 58–63.

    Article  CAS  Google Scholar 

  25. Miller DG, Adam MA, Miller AD . Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239–4242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hurley MJ, Bradford HF, O'Hare K, Stern GM, Uchida K . Neural toxicity of retroviruses. Neurosci Lett 1996; 220: 66–68.

    Article  CAS  PubMed  Google Scholar 

  27. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL . Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995–2002.

    Article  CAS  PubMed  Google Scholar 

  28. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M . Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 1997; 57: 2681–2686.

    CAS  PubMed  Google Scholar 

  29. Addison CL, Bramso JL, Hitt MM, Muller WJ, Gauldie J, Graham FL . Intratumoral coinjection of adenoviral vectors expression IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998; 5: 1400–1409.

    Article  CAS  PubMed  Google Scholar 

  30. Lehrman S . Virus treatment questioned after gene therapy death. Nature 1999; 40: 517–518.

    Article  Google Scholar 

  31. Saffran DC, Horton HM, Yankauchas MA, Anderson D, Barnhart KM, Abai AM et al. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Ther 1998; 5: 321–330.

    CAS  PubMed  Google Scholar 

  32. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531–2534.

    CAS  PubMed  Google Scholar 

  33. Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang NS . Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22: 135–144.

    Article  CAS  PubMed  Google Scholar 

  34. Weber SM, Shi FS, Heise C, Warner T, Mahvi DM . Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors. Ann Surgical Oncol 1998; 6: 186–194.

    Article  Google Scholar 

  35. Oshikawa K, Shi F-S, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS . Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1 β converting enzyme cDNA. Proc Natl Aca Sci USA 1999; 96: 13351–13356.

    Article  CAS  Google Scholar 

  36. Tahara H, Zitvogel L, Storkus WJ, Zeh III HJ, McKinney TG, Schreiber RD et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466–6474.

    CAS  PubMed  Google Scholar 

  37. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA et al. Cancer immunotherapy of established tumors with IL-12 Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393–1403.

    CAS  PubMed  Google Scholar 

  38. Missol E, Sochanik A, Szala S . Introduction of murine IL-4 gene into B16 (F10) melanoma tumors by direct gene transfer with DNA–liposome complexes. Cancer Lett 1995; 97: 189–193.

    Article  CAS  PubMed  Google Scholar 

  39. Parker SE, Ducharme S, Norman J, Wheeler CJ . Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997; 8: 393–401.

    Article  CAS  PubMed  Google Scholar 

  40. Stephan DJ, Yang ZY, San H, Simari RD, Wheeler CJ, Felgner PL et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996; 7: 1803–1812.

    Article  CAS  PubMed  Google Scholar 

  41. Blezinger P, Freimark BD, Matar M, Wilson E, Singhal A, Min W et al. Intratracheal Administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 1999; 10: 723–731.

    Article  CAS  PubMed  Google Scholar 

  42. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE . A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96: 1553–1558.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S et al. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Therapy 1999; 6: 833–839.

    Article  CAS  PubMed  Google Scholar 

  44. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205–216.

    Article  CAS  PubMed  Google Scholar 

  45. Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996; 7: 1535–1543.

    Article  CAS  PubMed  Google Scholar 

  46. Schultz J, Pavlovic J, Strack B, Nawrath M, Moelling K . Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum Gene Ther 1999; 10: 407–417.

    Article  CAS  PubMed  Google Scholar 

  47. Popovic D, El-Shami KM, Vadai E, Feldman M, Tzehoval E, Eisenbach L et al. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine Interleukin 12. Clin Exp Met 1998; 7: 623–632.

    Article  Google Scholar 

  48. Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W et al. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 1998; 9: 2481–2492.

    Article  CAS  PubMed  Google Scholar 

  49. Yahata T, Watanabe K, Ohta A, Sato N, Santo K, Abe N et al. Accumulation of IL-12-activated antitumor effector cells into lymph nodes of tumor-bearing mice. Immunol Lett 1998; 61: 127–133.

    Article  CAS  PubMed  Google Scholar 

  50. Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA et al. Safety of IL-12 gene therapy against cancer: A murine biodistribution and toxicity study. Hum Gene Ther 2003; 14: 1037–1048.

    Article  CAS  PubMed  Google Scholar 

  51. Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK . IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 2006; 29: 10–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Surgery, University of Wisconsin, Madison, WI, USA

    D M Mahvi, M B Henry, S Weber & K Meredith

  2. Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA

    D M Mahvi, M R Albertini, S Weber, H Schalch, A Rakhmilevich, J Hank & P Sondel

Authors
  1. D M Mahvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M B Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M R Albertini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Meredith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Schalch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Rakhmilevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Hank
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Sondel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D M Mahvi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahvi, D., Henry, M., Albertini, M. et al. Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial. Cancer Gene Ther 14, 717–723 (2007). https://doi.org/10.1038/sj.cgt.7701064

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7701064

Keywords

This article is cited by

Search

Advanced search

Quick links